Supplement guide
General

Octacosanol

Octacosanol is a long-chain (C28) saturated fatty alcohol found in plant waxes and as a major component of policosanol mixtures. It has been studied for effects on exercise endurance and lipid metabolism, but human evidence is limited and often comes from policosanol blends rather than isolated octacosanol.

1-Octacosanol
C28 alcohol
Octacosyl alcohol
Plant wax alcohol
Policosanol component

This guide covers all common forms and variations of octacosanol in one place. Use the sections below to find the form that fits your situation.

How it works in the body

Octacosanol is a long-chain aliphatic alcohol incorporated into plant cuticular waxes. In mammalian systems it is lipophilic and appears to influence lipid metabolism and energy pathways. Proposed mechanisms include modulation of hepatic lipid handling, effects on cholesterol biosynthesis, and changes in fatty acid oxidation and mitochondrial activity. Most mechanistic work derives from cell cultures and animal models; translation to humans has not been confirmed.

Octacosanol is also a principal component of policosanol mixtures. Biological effects attributed to policosanol — including altered platelet aggregation and LDL lowering — likely reflect the combined action of multiple long-chain alcohols rather than octacosanol alone. Preclinical studies report that octacosanol can activate AMPK-related pathways in muscle and liver, which could plausibly support endurance and alter lipid handling; these pathways have not been consistently demonstrated in human trials with isolated octacosanol.

Octacosanol molecular structure
2D molecular structure from PubChem, National Library of Medicine.

Body systems

Cardiovascular system
Musculoskeletal/endurance
Metabolic regulation
Nervous system

Associated molecules

Octacosanol
Policosanol (mixture)
Long-chain fatty alcohol metabolites

Track it lightly

If you decide to try octacosanol, track objective measures — exercise performance and/or lipid panel — and any side effects for at least 6–12 weeks before drawing conclusions.

Trying this? Start tracking it here.

Background

Octacosanol was characterized as a common long-chain alcohol in plant waxes (wheat germ, rice bran, sugarcane) through phytochemistry research during the 20th century. Clinical interest grew when Cuban researchers developed policosanol — a purified sugarcane wax mixture containing octacosanol as a major constituent — and reported cholesterol-lowering and cardioprotective effects in trials during the 1990s. That work drove international commercialization of both policosanol and isolated octacosanol supplements. Subsequent independent trials and systematic reviews produced mixed results, generating ongoing debate about reproducibility and mechanism. Octacosanol is now marketed both as an isolated ingredient and within policosanol blends; regulatory status and clinical recommendations vary by country, and evidence remains preliminary for most human outcomes.

Evidence snapshot

Preclinical studies (rodent and cell models) indicate octacosanol affects energy metabolism, mitochondrial function, and fatty acid oxidation. Some animal studies report increased exercise endurance and improved metabolic markers. Mechanistic data are preliminary and not fully consistent across models.

Clinical human evidence for isolated octacosanol is sparse. Most clinical literature tests policosanol — a mixture of long-chain alcohols in which octacosanol is often a major component. Early trials, particularly those originating from Cuba, reported lipid-lowering effects; independent trials and meta-analyses outside those research groups produced mixed or null results, and trial quality and reproducibility have been questioned.

Small studies and product reports suggest modest benefits for perceived energy and exercise capacity, but randomized, well-controlled trials using purified octacosanol are limited. Short-term safety data are generally reassuring; long-term safety and interactions with antiplatelet or anticoagulant therapy are not well established.

Bioavailability & formulation

Octacosanol is highly lipophilic and poorly soluble in water; absorption is meaningfully improved when taken with dietary fat. Commercial formulations include isolated octacosanol, policosanol mixtures (containing multiple long-chain alcohols), and whole extracts from wheat germ or sugarcane wax. Standardized policosanol products typically specify the total long-chain alcohol content rather than octacosanol specifically. Emulsified or oil-based capsules generally offer better uptake than dry powder tablets.

Populations studied

Most human evidence involves adults with hypercholesterolemia or healthy volunteers in exercise performance studies. A substantial portion of the lipid-outcome literature originates from Cuban clinical trials of policosanol; independent groups have reported inconsistent findings. Data are limited for older adults, individuals on multiple cardiovascular medications, pregnant women, and children — caution is warranted in these groups.

Long-term safety

Short-term trials (weeks to months) generally report few adverse events with policosanol or octacosanol. Robust long-term randomized data are absent. Because laboratory studies suggest effects on platelet function and lipid metabolism, monitoring is prudent when combining with antithrombotic or lipid-lowering medications over extended periods. Post-marketing surveillance data are limited.

Evidence quality & research gaps

Key limitations include small sample sizes, heterogeneity of preparations (isolated octacosanol versus policosanol blends of varying composition), and geographic concentration of positive trials. High-quality, independent randomized controlled trials of purified octacosanol using objective endpoints — standardized exercise tests, validated lipid panels — are needed. Mechanistic studies in humans are scarce.

Compound variations

Policosanol (mixture)

Octacosanol

A commercially studied mixture of long-chain alcohols (including octacosanol) typically extracted from sugarcane wax, wheat germ, or rice bran. Most human clinical data on lipids derive from policosanol products.

Common use case

Historically used in trials for cholesterol management; most commonly tested in adults with hypercholesterolemia.

Dosage note

Commonly studied doses: 5–20 mg/day; frequent clinical dose 5–10 mg/day. Composition varies by manufacturer.

Isolated octacosanol

Octacosanol

Purified single-ingredient octacosanol sold in capsule or softgel form. Fewer clinical trials exist compared with policosanol blends.

Common use case

Individuals wanting a single-constituent product to attribute effects specifically to octacosanol.

Dosage note

Typical supplement doses range 10–30 mg/day; human trial data specific to isolated octacosanol are limited.

Wheat germ oil / extract

Octacosanol

Natural extracts from wheat germ containing octacosanol among other lipids and bioactives.

Common use case

Users preferring whole-food or multi-constituent extracts over isolated compounds.

Dosage note

Octacosanol content in wheat germ oil varies by product; labels may not standardize octacosanol content — look for standardized extracts where possible.

Sugarcane wax extract

Octacosanol

Source material for many policosanol products; contains a mix of long-chain alcohols including octacosanol.

Common use case

Traditional source for policosanol preparations used in most of the historical clinical trial literature.

Dosage note

Clinical doses for sugarcane-derived policosanol typically range 5–20 mg/day.

Dosage and best practices

Dosage principles

  • In policosanol mixture trials, common clinical doses ranged from 5–20 mg/day; many trials used 5–10 mg/day. This range is the primary reference point in the human literature.
  • Supplement products supplying isolated octacosanol commonly provide 10–30 mg/day. Because human trials specifically on isolated octacosanol are limited, 10–20 mg/day aligns with amounts used in policosanol trials and current product practice.
  • For ergogenic use, some small studies and commercial protocols have used 20–25 mg/day. Allow 4–8 weeks and track objective performance metrics before concluding benefit or lack of benefit.

Best practices

  • Take octacosanol with a fat-containing meal to improve absorption; it is lipophilic and absorption is enhanced in the presence of dietary fat.
  • If testing effects on endurance or lipids, track objective measures (e.g., timed exercise tests, VO2, or fasting lipid panel) over 6–12 weeks. Placebo response is large for subjective energy outcomes.
  • Prefer products that specify policosanol composition or isolated octacosanol content. Products labeled simply 'policosanol' contain a mixture of alcohols whose octacosanol percentage varies by manufacturer and source.

Literature and references

Common questions

Is octacosanol the same as policosanol?

No. Octacosanol is a single long-chain fatty alcohol (C28). Policosanol is a mixture of long-chain alcohols, typically extracted from sugarcane wax, wheat germ, or rice bran, that contains octacosanol alongside other alcohols such as triacontanol and hexacosanol. Most clinical studies test policosanol mixtures rather than pure octacosanol.

Will octacosanol lower my cholesterol?

Evidence is inconsistent. Early policosanol trials reported LDL reductions, but independent studies and meta-analyses found variable results. Direct evidence for isolated octacosanol lowering cholesterol in controlled trials is limited. Consult your clinician before adding octacosanol to an existing lipid-lowering regimen.

Can octacosanol improve exercise performance?

Animal data and a small number of human studies suggest possible improvements in endurance or perceived exertion. High-quality human trials of isolated octacosanol are lacking. If trialing for performance, track objective measures (e.g., time trials, VO2) over several weeks to verify any benefit.

Are there safety concerns?

Short-term use appears generally well tolerated, with occasional mild side effects (GI upset, headache). Safety in pregnancy and lactation is unknown. Use caution with anticoagulant or antiplatelet drugs and consult a healthcare provider before combining.

How long before I see effects?

Available studies suggest allowing at least 4–12 weeks to evaluate changes in exercise performance or blood lipids. Individual responses vary, and placebo effects are substantial for subjective outcomes such as energy.